American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions. Read More ›

New Immunotherapy Treatment Looks Promising in Relapsed/Refractory Multiple Myeloma

ASH 2019 – Multiple Myeloma: Wrap-Up

CAR T-cell therapy, a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells, has led to exciting results in other types of cancer…could it soon be used to treat multiple myeloma? Read More ›

Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs. Read More ›

ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

The results of this phase 3 study demonstrate a progression-free survival advantage for patients treated with acalabrutinib given alone or in combination with obinutuzumab versus those treated with obinutuzumab plus chlorambucil. Read More ›

Acalabrutinib-Based Combination Treatments for CLL

ASH 2019 – CLL

Results from ELEVATE-TN, a phase 3 study comparing the efficacy and safety of acalabrutinib given as a single agent; acalabrutinib combined with obinutuzumab; and obinutuzumab combined with chlorambucil in patients with untreated chronic lymphocytic leukemia (CLL). Read More ›

Combination Treatment for Follicular Lymphoma

ASH 2019 – CLL

Researchers tested the Pola-G-Len (polatuzumab vedotin, obinutuzumab, and lenalidomide) regimen to determine if it enhanced antitumor response in patients with relapsed or refractory follicular lymphoma. Read More ›

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features. Read More ›

Third Interim Analysis from the Phase 2 Vision HO141 Trial of Venetoclax + Ibrutinib for Patients with R/R CLL: 15-Month Safety, Response, and MRD Evaluation

ASH 2019 – CLL

American Society of Hematology (ASH)

Page 18 of 44